Biomarker-based Study in R/M SCCHN

NCT03088059 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

340

Enrollment

NETWORK

Sponsor class

Conditions

Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: Afatinib
DRUG: Palbociclib
DRUG: standard of care
DRUG: IPH2201
DRUG: Durvalumab
DRUG: Niraparib
DRUG: INCAGN01876

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC